Loading...
01/10 19:12
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary indicates several negative factors: declining international sales, supply chain disruptions, a significant drop in gross margin, increased operating expenses, and widening losses. Although there is some positive news, such as the sale of the Venus Hair business and a slight increase in U.S. revenue, the overall financial health and strategic uncertainties outweigh these. The lack of full-year guidance and high debt obligations further contribute to a negative outlook, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Total Revenue $15.7 million, down $0.9 million or 5% year-over-year. The decrease was driven by an 18% decrease in international revenue, partially offset by a 5% increase in U.S. revenue.
Gross Profit $9.4 million, down $2.4 million or 20% year-over-year. The decline was due to customer uncertainty about economic stability, tighter third-party lending practices, decreased international revenue, and supply disruptions caused by the Israel-Iran conflict.
Gross Margin 60.1% of revenue, down from 71.5% in the second quarter of 2024. The decrease was due to supply disruptions, adverse sales mix, and higher manufacturing overhead costs.
Operating Expenses $18.5 million, up $1 million or 6% year-over-year. The increase reflects progress in cost containment and streamlining operations.
GAAP Operating Loss $9.0 million, compared to $5.6 million in the second quarter of 2024. The increase was due to higher operating expenses and lower gross profit.
Net Loss Attributable to Stockholders $11.7 million or $8.03 per share, compared to $20.0 million or $30.93 per share in the second quarter of 2024. The improvement was driven by lower net interest and other expenses.
Adjusted EBITDA Loss $8.8 million, compared to $4.1 million in the second quarter of 2024. The increase was due to higher operating losses.
Cash and Cash Equivalents $4.9 million as of June 30, 2025, compared to $4.3 million as of December 31, 2024. The increase was due to equity capital market transactions and debt exchanges.
Total Debt Obligations $34.3 million as of June 30, 2025, compared to $39.7 million as of December 31, 2024. The decrease was due to debt exchanges and amendments with the primary lender.
Bliss MAX, Versa Pro, and Viva MD: Focus on prioritizing these core products in the U.S. market to improve sales efficiency.
Next body device: Planned launch by early 2026, targeting complementary benefits for consumers using weight loss medications.
U.S. market: Achieved 5% year-over-year growth in sales, driven by double-digit growth in total systems and subscription revenue.
International market: Faced an 18% year-over-year decline in sales due to macroeconomic headwinds, tariffs, and distributor demand challenges.
Revenue performance: 15% quarter-over-quarter growth in Q2 2025, driven by 20% growth in total systems and subscription revenue.
Cash system sales: Increased to 65% of total U.S. system sales in Q2 2025, up from 58% last year, as part of a strategy to enhance profitability.
Sale of Venus Hair business: Sold to Meta Health Group for $20 million in an all-cash transaction to focus on global medical aesthetics business and improve financial health.
Strategic alternatives: Ongoing evaluation to maximize shareholder value, including targeted investments and cost management.
Global capital equipment environment: Uncertainty in the timing and pace of new systems adoption across the aesthetic sector due to customer financing pressures, economic uncertainty, high interest rates, tighter credit markets, and proposed tariffs.
International business exposure: International sales declined 18% year-over-year, with exposure to macroeconomic headwinds, including tariffs and distributor demand impacts.
Supply chain disruptions: Supply disruptions caused by the Israel-Iran conflict impacted production at the contract manufacturer's facility in Israel, leading to shortages of higher-margin devices and adverse sales mix.
Gross profit and margin decline: Gross profit decreased by 20% year-over-year, and gross margin dropped from 71.5% to 60.1%, driven by supply disruptions, higher device system costs, and lower sales volume.
Operating expenses and losses: Operating expenses increased by 6%, and GAAP operating loss widened to $9.0 million compared to $5.6 million in the prior year.
Debt obligations and financial condition: Total debt obligations remain high at $34.3 million, and the company reported a net loss of $11.7 million for the quarter.
Strategic execution risks: The company is undergoing strategic transitions, including the sale of the Venus Hair business and repositioning towards cash system sales, which carry execution risks and potential disruptions.
Revenue Growth: The company expects to launch its next body device by early 2026, which is anticipated to drive growth. Additionally, the sale of the Venus Hair business is expected to improve revenue growth and enhance the cash flow profile of the business.
Market Trends: The company views the increase in GLP-1 usage by consumers as a catalyst for the industry, providing an opportunity to highlight the complementary benefits of its body technology, particularly skin tightening, to customers on weight loss medications.
Strategic Focus: The company is prioritizing cash system sales to enhance long-term profitability and is managing cash burn through disciplined cost management and targeted investments to support long-term growth.
Financial Guidance: The company is not providing full-year 2025 financial guidance due to ongoing evaluations with lenders, investors, and strategic alternatives, as well as market conditions impacted by trade disruptions.
The selected topic was not discussed during the call.
The company's financial performance shows declining revenue and increased losses, with challenges in the hair restoration business and economic uncertainties. Despite some positive developments, such as the sale of the Venus Hair business and strategic focus on growth, the lack of guidance and increased debt obligations weigh negatively. The absence of Q&A insights further limits positive sentiment. Overall, the negative financials and uncertainties overshadow potential growth catalysts, leading to a negative outlook.
The earnings call summary indicates several negative factors: declining international sales, supply chain disruptions, a significant drop in gross margin, increased operating expenses, and widening losses. Although there is some positive news, such as the sale of the Venus Hair business and a slight increase in U.S. revenue, the overall financial health and strategic uncertainties outweigh these. The lack of full-year guidance and high debt obligations further contribute to a negative outlook, likely leading to a stock price decline of -2% to -8% over the next two weeks.
The earnings call reveals significant challenges: a 22% revenue decline, increased operating loss, and lack of full-year guidance. Despite debt reduction and strategic shifts, the market conditions and financial strain are concerning. The Q&A highlighted uncertainties, particularly around tariffs and sales delays. While there is potential with the new product, the lack of specifics and distributor hesitancy add to the negative sentiment. Without a clear shareholder return plan and with financial metrics pointing to struggles, the stock is likely to experience a negative reaction.
The earnings call reflects a negative sentiment due to several factors: a significant revenue decline (22% YoY), increased operating losses, and a lack of financial guidance for 2025. The Q&A revealed concerns about tariffs and unclear management strategies, adding to uncertainties. Although debt was reduced and a new product launch is anticipated, these positives are overshadowed by weak financial performance and market challenges. Without share repurchases or dividends, shareholder returns are stagnant. These factors suggest a likely negative stock price reaction in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
